Prothena Biosciences

News

Roche and Prothena's alpha-synuclein-targeting prasinezumab for Parkinson's fails again, leaving them sifting through the data for efficacy signals.

News

Senior figures in European biopharma think dealmaking and M&A will increase in the region, and could be helped by US policy uncertainties.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.